CureVac COVID vaccine let-down spotlights mRNA design challenges.

Dolgin, Elie

Dolgin, Elie.

Nature ; 594(7864): 483, 2021 06.

Article in English | MEDLINE | ID: covidwho-1286424

Subject(s)

Antibodies, Neutralizing/analysis; Antibodies, Neutralizing/immunology; COVID-19 Vaccines/chemistry; COVID-19 Vaccines/immunology; Vaccines, Synthetic/chemistry; Vaccines, Synthetic/immunology; 2019-nCoV Vaccine mRNA-1273; Animals; BNT162 Vaccine; COVID-19 Vaccines/administration & dosage; COVID-19 Vaccines/adverse effects; Clinical Trials, Phase I as Topic; Cold Temperature; Drug Storage; Germany; Haplorhini; Humans; Pseudouridine/genetics; Pseudouridine/immunology; Pseudouridine/metabolism; RNA Stability; Rats; Vaccines, Synthetic/administration & dosage; Vaccines, Synthetic/adverse effects

Keywords

SARS-CoV-2; Vaccines

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Antibodies, Neutralizing / COVID-19 Vaccines Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Country/Region as subject: Europa Language: English Journal: Nature Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google